A LYSA Phase Ib Study of Tazemetostat (EPZ-6438) plus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) with Poor Prognosis Features.

Clémentine SarkozyFranck MorschhauserSydney DuboisThierry MolinaJean Marie MichotPeggy Cullières-DartiguesBenjamin Suttle Lionel KarlinSteven Le GouillJean-Michel PicquenotRomain DuboisHervé TillyCharles HerbauxFabrice JardinGilles SallesVincent Ribrag

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

The RP2D of tazemetostat combined with R-CHOP is 800 mg twice a day. The association presents safety and PK comparable with R-CHOP alone. Preliminary efficacy data are encouraging and further investigations in phase II trial are warranted.

Keyphrases

diffuse large b cell lymphoma
poor prognosis
epstein barr virus
newly diagnosed
long non coding rna
electronic health record
big data
open label
clinical trial
machine learning
data analysis
artificial intelligence